The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immunosuppressive Treatment for Lupus in the Next Decade

Immunosuppressive Treatment for Lupus in the Next Decade

April 13, 2011 • By Dimitrios T. Boumpas, MD; George Bertsias, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

More recently, in an effort to reconcile divergent opinions and minimize the risk of over- or undertreating, we proposed a risk stratification scheme with low-, intermediate-, and high-risk categories (see Figure 2, p. 43). According to this approach, patients at higher risk for ESRD should be treated more aggressively, whereas those at lower risk can be treated less aggressively.9,10 Failure to achieve a major response within the first four to six months should evoke consideration for intensifying therapy. Although based on data originating from various centers, this strategy has not been evaluated in the context of a trial.

You Might Also Like
  • Best Lupus Treatment Still Up for Debate
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
Explore This Issue
April 2011

We should focus our efforts on developing a more comprehensive strategy to guide the treatment of lupus. This strategy should both “fit the patient” and achieve timely and long-lasting remission with the lowest possible harm.

Mycophenolate Mofetil

Although, in some centers, the intense debate regarding the use of CY continued until the end of the millennium, a “new kid on the block” by the name of MMF appeared from the field of transplantation. Thus, at the beginning of this decade, several RCTs with short-to-medium–term (up to five years) follow-up claimed that MMF has at least comparable—if not superior—efficacy to CY in the treatment of proliferative LN. These studies generated a great deal of enthusiasm, passion, and anticipation in the community, with several investigators declaring the end of the CY era in national and international forums. Soon, a large multicenter, multiracial RCT (the Aspreva Lupus Management Study, or ALMS) was conducted, aiming to demonstrate superiority of MMF as induction and maintenance therapy.11 Patients with class III-V LN were initially randomized to receive open-label induction therapy with MMF (target dose 3 g/day) or IV-CY (0.5–1.0 g/m2 in monthly pulses) in combination with cortico­steroids (tapered from a maximum dose of 60 mg/day) for 24 weeks. Patients achieving response or complete remission (primary outcome) were subsequently re-randomized to double-blind, placebo-controlled maintenance treatment with MMF or AZA, both plus corticosteroids.12 For the maintenance phase, the primary endpoint was time to treatment failure (defined as either flares, need to intensify therapy, doubling of serum creatinine, or death).

The ALMS-induction trial did not detect significantly different response rates between the two groups. Of interest, MMF responses were better in certain racial/ethnic groups such as black-race and mixed Latin American (Hispanic) patients. During the maintenance phase, the investigators found a failure rate of 32% in the AZA group versus 16% in the MMF group at three years. In contrast, Houssiau and colleagues reported that MMF and AZA were comparable as maintenance therapy for proliferative LN in a multicenter European trial.13 While awaiting the full report on ALMS-maintenance to sort out whether these results reflect differences in the outcomes used (single in the MAINTAIN trial, composite in ALMS), the number (n=105 in MAINTAIN, n=227 in ALMS) or ethnic background of the patients, the MAINTAIN study clearly demonstrates equivalence between AZA and MMF in European patients with moderately severe LN.14

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Figure 2: A risk-stratification strategy for the management of proliferative lupus nephritis.
click for large version
Figure 2: A risk-stratification strategy for the management of proliferative lupus nephritis.
  1. Stratification of risk for progression to end-stage renal disease based on findings of longitudinal observational studies, and retrospective analyses of RCTs or clinical cohorts. Adverse histology denotes the presence of crescents and/or fibrinoid necrosis affecting >25% of glomeruli; glomerular sclerosis, tubular atrophy, or chronicity index >4; or chronicity index >3 and activity index >10. Impaired renal function denotes increase in serum creatinine or reduction in estimated glomerular filtration rate (calculated by the Cockcroft-Gault or the Modification of Diet in Renal Disease formula) by >25%, or proteinuria >4 g/24 hr.
  2. Renal response is assessed at six months. CR is defined as decrease in proteinuria to <1 g/day (or <0.3 g/day in LN diagnosed in the past six months) with normal serum albumin concentrations; inactive urine sediment; and improved or stable renal function. PR is defined as significant change in proteinuria (if nephrotic at baseline ≥50% decrease in proteinuria to <3 g/day; if non-nephrotic at baseline but not meeting the CR criteria) and improved or stable renal function.

Abbreviations: CR, complete response; PR, partial response; NR, no response.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, SLE (Lupus) Tagged With: Diagnostic Criteria, Drugs, Pathogenesis, patient care, Systemic lupus erythematosus, TreatmentIssue: April 2011

You Might Also Like:
  • Best Lupus Treatment Still Up for Debate
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Lupus Nephritis Improvements: A 5-Decade Retrospective Review

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)